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bjectives We sought to evaluate the safety and feasibility of the Impella 2.5 system (Abiomed Inc.,
anvers, Massachusetts) in patients undergoing high-risk percutaneous coronary intervention (PCI).
ackground The Impella 2.5 is a miniaturized percutaneous cardiac assist device, which provides up
o 2.5 l/min forward ﬂow from the left ventricle into the systemic circulation.
ethods In a prospective, multicenter study, 20 patients underwent high-risk PCI with minimally
nvasive circulatory support employing the Impella 2.5 system. All patients had poor left ventricular
unction (ejection fraction 35%) and underwent PCI on an unprotected left main coronary artery
r last patent coronary conduit. Patients with recent ST-segment elevation myocardial infarction or
ardiogenic shock were excluded. The primary safety end point was the incidence of major adverse
ardiac events at 30 days. The primary efﬁcacy end point was freedom from hemodynamic compro-
ise during PCI (deﬁned as a decrease in mean arterial pressure below 60 mm Hg for 10 min).
esults The Impella 2.5 device was implanted successfully in all patients. The mean duration of circula-
ory support was 1.7  0.6 h (range: 0.4 to 2.5 h). Mean pump ﬂow during PCI was 2.2  0.3 l/min. At
0 days, the incidence of major adverse cardiac events was 20% (2 patients had a periprocedural myo-
ardial infarction; 2 patients died at days 12 and 14). There was no evidence of aortic valve injury, car-
iac perforation, or limb ischemia. Two patients (10%) developed mild, transient hemolysis without clini-
al sequelae. None of the patients developed hemodynamic compromise during PCI.
onclusions The Impella 2.5 system is safe, easy to implant, and provides excellent hemody-
amic support during high-risk PCI. (The PROTECT I Trial; NCT00534859) (J Am Coll Cardiol Intv
009;2:91–6) © 2009 by the American College of Cardiology Foundation
rom *William Beaumont Hospital, Royal Oak, Michigan; †Academic Medical Center, Amsterdam, the Netherlands; ‡Brigham
nd Women’s Hospital, Boston, Massachusetts; §Texas Heart Institute, Houston, Texas; Scripps Clinic, La Jolla, California;
Cedars Sinai, Los Angeles, California; #Massachusetts General Hospital, Boston, Massachusetts; **Columbia Presbyterian, New
ork, New York; ††Abiomed Inc., Danvers, Massachusetts; and the ‡‡University of Miami, Miami, Florida. Supported by a grant
rom Abiomed Inc., Danvers, Massachusetts. Dr. Benali is a paid employee of Abiomed Inc. Presented in part at Transcatheter
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92n patients with poor left ventricular (LV) function under-
oing high-risk percutaneous coronary intervention (PCI),
ven brief episodes of myocardial ischemia may result in
ypotension and decreased cardiac output leading to a
icious cycle of coronary hypoperfusion, heart failure, and
emodynamic collapse. Accordingly, prophylactic stabiliza-
ion is often employed in these high-risk patients to prevent
emodynamic instability and adverse periprocedural out-
omes. The Impella 2.5 system (Abiomed Inc., Danvers,
assachusetts) is a novel, minimally invasive LV assist
evice, which is placed retrogradely across the aortic valve
ia the femoral artery using conventional catheterization
echniques (1). Using a miniaturized rotary pump, blood is
rawn from the LV cavity and expelled into the ascending
orta, providing up to 2.5 l/min forward flow at its maxi-
um rotation of 51,000 rpm. Initial clinical studies have
emonstrated that the Impella device effectively unloads the
V, improves coronary perfusion, and augments cardiac
utput (2,3). The PROTECT I (A Prospective Feasibility
rial Investigating the Use of the IMPELLA RECOVER
P 2.5 System in Patients Undergoing High Risk PCI) trial
was designed to evaluate the
safety and feasibility of the Im-
pella 2.5 system in patients un-
dergoing high-risk PCI.
Methods
Study population. The PRO-
TECT I trial enrolled 20 pa-
tients undergoing high-risk,
nonemergent PCI at 7 centers
between July 2006 and April 17,
007 (investigational device exemption: G050017). Eligible
atients had a LV ejection fraction (EF) 35% and were
equired to undergo PCI on either an unprotected left main
oronary artery or the last patent coronary conduit. Exclu-
ion criteria were: age 40 or 80 years, ST-segment
levation myocardial infarction within 7 days; pre-procedure
ardiac arrest within 24 h of enrollment requiring cardio-
ulmonary resuscitation; cardiogenic shock (defined as car-
iac index 2.2 l/min/m2 and pulmonary capillary wedge
ressure 15 mm Hg); LV mural thrombus; presence of a
echanical aortic valve or a heart constrictive device; aortic
tenosis (valve area 1.5 cm2); moderate or severe aortic
egurgitation (2 by echocardiography); severe peripheral
ascular disease that would preclude placement of the
mpella 2.5 device; chronic renal dysfunction (serum creat-
nine 3.5 mg/dl); history of liver dysfunction with eleva-
ion of the liver enzymes and bilirubin 3 times the upper
imit of normal or international normalized ratio (INR)
2.0; severe pulmonary disease (FEV1 1.0); uncorrect-
ble abnormal coagulation parameters (defined as platelet
bbreviations
nd Acronyms
F  ejection fraction
NR  international
ormalized ratio
V  left
entricle/ventricular
CI  percutaneous
oronary interventionount 75,000 or INR 2.0 or fibrinogen 1.5 g/l); iubjects with sustained or nonsustained ventricular tachy-
ardia; active systemic infection; stroke or transient ischemic
ttack within 3 months; allergy or intolerance to aspirin,
lopidogrel, heparin, or contrast media; patients with
eparin-induced thrombocytopenia; or participation in an-
ther investigational drug or device trial. The study was
pproved by the institutional review board at each center.
ritten informed consent was obtained from each patient
efore enrollment.
mpella system. The Impella 2.5 device is a miniaturized
2-F rotary blood pump that is placed across the aortic valve
Fig. 1). The device aspirates blood from the LV cavity,
hich is then expelled into the ascending aorta. Under
linical conditions, the pump provides up to 2.5 l/min at its
aximal rotation speed of 51,000 rpm. The device is
nserted percutaneously through a 13-F femoral sheath and
s mounted on a 9-F pigtail catheter, allowing it to be easily
laced across the aortic valve, and left in place for up to 5
ays. The Impella 2.5 catheter is connected distally to a
ortable mobile console that displays invasive pressure with
he actual revolutions per minute of the pump, thus guiding
he correct positioning and functioning of the device.
mpella procedure. After insertion of a 13-F femoral arterial
heath, the Impella 2.5 system was advanced retrogradely
cross the aortic valve using a monorail technique and
ositioned in the mid-LV cavity. All patients were antico-
gulated with unfractionated heparin before pump insertion
o achieve an activated clotting time 250 s. The pump
equires an activated clotting time of 160 to 180 s during
peration. Circulatory support was initiated before PCI
ith a target flow of 2.5 l/min. PCI was then performed
sing conventional equipment and techniques. Glycopro-
ein receptor inhibitors were administered at the operator’s
iscretion. The timing of device explanation was left to the
iscretion of the physician. For patients who were hemo-
ynamically stable during PCI, weaning was commenced in
he cardiac catheterization laboratory by decreasing the
ump performance level in 2 steps in intervals of 2 to 10
in. Once the performance level was reduced to perfor-
ance level P2 (range: P1 to P9; P9  maximum flow) for
0 min without hemodynamic instability, the Impella pump
as pulled back into the aorta and explanted. In patients in
hom weaning was unable to be achieved in the catheter-
zation laboratory, the Impella 2.5 could remain implanted
or up to 5 days. Manual compression was used to achieve
emostasis.
tudy procedures. Transthoracic echocardiography was
erformed before and after pump implantation, at pump
emoval, and 30 days after the procedure. Studies were
nalyzed at the Duke University Core Echocardiographic
aboratory. Hemodynamic measurements were recorded
efore support and every 30 min until the device was
emoved. Serial blood sampling was obtained before, dur-
ng, and after Impella support for cardiac enzymes, hemo-
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93ysis, biochemistry, blood gases, and hematology. Neurolog-
cal assessment was performed before PCI and daily until
ospital discharge.
ata management and analysis. Study data, collected pro-
pectively by research coordinators, were verified against
ource documentation by trial monitors. An independent
ommittee adjudicated all adverse clinical events. All inves-
igators had access to study data.
tudy end points and deﬁnitions. The primary safety end
oint was the incidence of major adverse cardiac events
efined as death, myocardial infarction, target vessel revas-
ularization, urgent coronary artery bypass surgery, or stroke
t 30 days. Secondary safety end points included aortic valve
njury, aortic insufficiency, cardiac tamponade, cardiogenic
hock, device malfunction, hemolysis, hepatic failure, inser-
ion site infection, limb ischemia, perforation, renal failure,
espiratory failure, sepsis, thrombocytopenia, thrombotic
noncentral nervous system) complication, transfusion, vas-
ular injury, ventricular fibrillation, and ventricular tachy-
ardia. The primary efficacy end point was freedom from
emodynamic compromise during PCI, defined as a de-
rease in the mean arterial pressure below 60 mm Hg for
ore than 10 min or the requirement for additional pressor
upport. Secondary efficacy end points were freedom from
rocedural-related events (ventricular fibrillation, tachycar-
ia requiring electrical cardioversion), and angiographic
uccess was defined as residual stenosis 30% after stent
Figure 1. Photograph of the Impella 2.5 Catheter
Photograph of the Impella 2.5 catheter positioned across the aortic valve.mplantation or 50% after balloon angioplasty alone. (yocardial infarction was defined as an increase of the
reatine kinase-myocardial band3 times the upper limit of
ormal.
esults
linical data. A total of 20 patients were enrolled at 7 sites
n 2 countries (6 in the U.S., 1 in the Netherlands). All
atients had poor LV function (mean EF: 26  6%, range:
5% to 35%) and multiple comorbidities including prior
yocardial infarction (60%) and congestive heart failure
85%) (Table 1). All patients underwent PCI on a vessel
upplying a large proportion of the myocardium (n  14
nprotected left main coronary artery; n  6 on a last
emaining conduit) (Table 2). The mean number of lesions
reated was 2.4  0.9.
rocedural data. The Impella device was implanted success-
ully in all patients. The mean duration of circulatory
upport was 1.7  0.6 h (range: 0.4 to 2.5 h). Mean pump
ow was 2.2  0.3 l/min during PCI, and 1.2  0.4 l/min
uring pump weaning. All patients had the Impella 2.5
evice removed uneventfully in the cardiac catheterization
aboratory after PCI. There were no cases of device mal-
unction. The mean arterial pressure and heart rate were
table during pump support. Compared with baseline pa-
ameters, a small decrease in systolic, diastolic, and mean
rterial pressure was observed after the device was removed
Table 3). Mean procedure time was 3.3  0.9 h.
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94rimary safety end point. At 30 days, the primary safety end
oint had occurred in 4 (20%) patients (Table 2). Two
atients had enzymatic evidence of a periprocedural myo-
ardial infarction without clinical sequelae (1 occurred in a
atient undergoing rotational atherectomy and stenting of
Table 1. Clinical Characteristics (N  20)
Age, yrs 60 12
Male 17 (85%)
BMI, kg/m2 27.5 4.4
Diabetes mellitus 9 (45%)
Hypertension 10 (50%)
Hyperlipidemia 15 (75%)
Congestive heart failure 17 (85%)
Class IV 7 (35%)
Class III 5 (25%)
Current smoker 8 (40%)
Previous MI 12 (60%)
Previous PCI 9 (45%)
Previous CABG 8 (40%)
COPD 7 (35%)
Renal failure 9 (45%)
Pacemaker/ICD 7 (35%)
BMI  body mass index; CABG  coronary artery bypass graft; COPD  chronic obstructive
pulmonary disease; ICD  implantable cardioverter-defibrillator; MI  myocardial infarction;
PCI percutaneous coronary intervention.
Table 2. Procedural and Outcome Data
Patient #
Age,
yrs Sex EF
Target
Vessel
Lesions
Treated (n)
Duration of
Support (h)
1 64 F 25 ULM 3 1.5
2 80 M 35 LPC 3 2.4
3 80 M 20 ULM 2 2.1
4 73 M 26 LPC 3 2.5
5 69 M 28 LPC 1 0.7
6 64 M 20 ULM 1 0.7
7 81 M 18 ULM 2 1.8
8 46 F 30 ULM 2 2.3
9 36 M 32 ULM 3 1.9
10 77 M 29 ULM 4 1.1
11 66 M 30 LPC 2 0.4
12 59 F 32 ULM 3 1.3
13 67 M 27 LPC 2 2.1
14 47 M 24 LPC 3 2.1
15 68 M 15 LPC 2 2.0
16 77 M 35 ULM 4 2.1
17 70 M 30 ULM 1 2.3
18 57 M 34 ULM 3 1.7
19 63 M 16 ULM 3 1.6
20 79 M 24 ULM 3 1.5
— not applicable; EF ejection fraction; LPC last patent conduit; MACEmajor adverse carunprotected left main; VT ventricular tachycardia; other abbreviations as in Table 1.he left main, left anterior descending, and circumflex
rteries; the other patient had a large dissection of the left
ain coronary artery with transient subtotal occlusion
uring PCI). No patients had a stroke, target vessel revas-
ularization, or coronary artery bypass graft surgery. There
ere 2 deaths: 12 and 14 days after PCI and device removal.
either death was related to the investigational device. One
atient, who had a history of severe cardiomyopathy, died
uddenly while in a cardiac rehabilitation center (day 14).
he other patient developed acute-on-chronic renal failure
nd progressive heart failure after PCI, culminating in
ardiac arrest on day 12.
econdary safety end points. Two patients had laboratory
vidence of mild hemolysis. In 1 patient, hemolysis was
bserved during pump use (peak plasma-free hemoglobin
5.8 mg/dl 1 h after insertion). The plasma-free hemoglo-
in had returned to normal 24 h after the device was
emoved. In the other patient, the plasma-free hemoglobin
as normal at device removal, but the level was elevated
4 h after removal (67.8 mg/dl). Neither patient required
reatment or had any clinical sequelae. Two patients re-
uired blood transfusion (1 patient had baseline anemia; the
ther patient had hematuria secondary to bladder cancer).
ight patients developed a hematoma at the Impella fem-
ral access site (diameter: 4 cm in 2 patients, 4 to 8 cm in
Pump Flow
ing PCI (l/min)
Angiographic
Success
MACE at
30 Days Secondary End Points
2.2 Y MI —
2.3 Y — —
2.0 Y — —
2.1 Y Death (day 14) —
2.1 Y — —
2.1 Y — —
2.0 Y — —
2.3 Y — —
2.3 Y — —
2.4 Y — Hemolysis
2.4 Y — —
2.5 Y — Transfusion
1.9 Y MI —
2.2 Y — VT
2.4 Y — —
2.4 Y — —
2.6 Y Death (day 12) Hemolysis, renal failure,
transfusion, VT
2.3 Y — —
2.1 Y — —
1.5 Y — —
nts; MImyocardial infarction; PCI percutaneous coronary intervention; Pt patient; ULMDur
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95patients, and unknown in 3 patients). None of the patients
equired invasive treatment of the hematoma. One patient
eveloped acute-on-chronic renal failure. Two patients had
entricular tachycardia secondary to their underlying cardiac
isease (1 patient on day 26 after the procedure; 1 patient on
ay 14 just prior to death). There were no cases of cardiac
erforation, vascular injury, or limb ischemia. No patients
eveloped evidence of neurologic dysfunction during or
fter Impella support.
fﬁcacy end points. The primary efficacy end point, free-
om from hemodynamic compromise, was observed in all
atients (100%). There were no cases of ventricular fibril-
ation or ventricular tachycardia requiring cardioversion
uring PCI. Angiographic success was achieved in all
atients.
chocardiographic ﬁndings. There was no echocardio-
raphic evidence of injury to the aortic or mitral valves, or
V during or after device use. One patient developed
oderate aortic regurgitation during pump support, but this
esolved after the device was removed. At 30 days, a
ollow-up echocardiogram was performed on 16 patients,
one of whom had moderate or severe aortic regurgitation.
n improvement in EF was observed at 30 days (pre-PCI:
F  26  6% vs. 30 days post-PCI: EF  34  11%,
 0.003).
iscussion
n the present study, we found that use of the Impella 2.5
ystem was safe and feasible during high-risk PCI in
atients with profound LV dysfunction and multiple co-
orbidities. The Impella 2.5 device was easy to implant,
erformed well, and was associated with a low rate of
dverse events.
emodynamic effects of the Impella pump. By continuously
spirating blood from the LV cavity, the Impella pump has
een shown to have a direct effect on LV unloading,
oronary flow, and overall cardiac output (2,3). Pressure-
olume loop recordings demonstrate a reduction in LV
nd-diastolic pressure and end-diastolic volume during
ump activation, which theoretically decreases LV wall
ension and myocardial oxygen demand. The Impella pump
lso has a favorable effect on coronary flow hemodynamics
Table 3. Hemodynamics With the Impella 2.5 System
Before Support
Systolic BP, mm Hg 123.5 23.6
Diastolic BP, mm Hg 65.7 11.5
Mean arterial pressure, mm Hg 84.5 14.3
Heart rate, beats/min 68.1 9.0
*Comparing before and after support values.
BP blood pressure.n humans (3). With increasing levels of Impella support, an Ancrease in mean distal coronary pressure (85  11 mm Hg
o 94 11 mm Hg, p 0.001), hyperemic flow velocity (61
24 cm/s to 72  27 cm/s, p  0.001), and coronary flow
eserve (1.88  0.52 to 2.34  0.63, p  0.001) has been
bserved. Additionally, a significant decrease in the coro-
ary microvascular resistance was seen that was perhaps
elated to collateral recruitment and the decrease in in-
ramyocardial pressure.
revious experience with Impella pump. Since its intro-
uction in Europe in 2004, the Impella 2.5 technology
as been used in a wide range of clinical settings
ncluding, but not limited to, high-risk PCI, cardiogenic
hock, acute myocardial infarction, postcardiotomy syn-
rome, and myocarditis (4 – 6). Henriques et al. (7)
eported use of the Impella 2.5 device in 19 patients
uring high-risk PCI (63% patients had EF 25%). The
mpella system was placed successfully in all patients, and
here were no device-related deaths or other serious
dverse events. One patient developed a groin hematoma
equiring transfusion.
afety of the Impella device. Because the Impella 2.5
evice requires placement across the aortic valve, there
re potential risks of injury to the valve or of inducing
ortic regurgitation by tenting open the valve leaflets.
etailed echocardiographic evaluation was therefore per-
ormed as part of this pilot trial. The Core Laboratory
nalysis showed no evidence of injury to the valve or
ignificant change in the degree of aortic insufficiency,
hich is consistent with observations from other clinical
tudies (7). Nor did we observe any cases of ventricular
rrhythmia related to the Impella catheter positioned in
he LV cavity. Another potential concern with the
mpella system is a risk of hemolysis that may be induced
y the high shear stress of the axial pump on red blood
ells. In the present study, we observed a small increase in
lasma-free hemoglobin in 1 patient during pump use;
owever, the rise was mild, transient, and did not require
reatment. Mild hemolysis has also been observed in
ther clinical studies but is usually transient and not
linically significant. An early increase may be observed
ithin the first 6 h of support, with a rapid decrease
hereafter even if patients are supported for several days.
On Support After Support p Value*
125.3 23.0 110.3 18.1 0.001
71.8 12.6 59.8 10.3 0.03
89.0 14.8 76.0 11.9 0.004
70.0 8.5 72.6 8.9 0.1dditionally, the Impella device requires insertion of a
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963-F sheath in the femoral artery, which may be associ-
ted with an increased risk of access site bleeding or
schemia. Indeed, we observed hematoma in 8 of the 20
atients enrolled in our study. Although none of these
atients required transfusion or vascular repair, we be-
ieve alternative strategies, including use of advanced
losure techniques, need to be studied in the future to
ddress this issue.
tudy limitations. Although we planned to measure car-
iac output and right heart hemodynamics at various
tages of the PCI procedure, including during balloon
cclusion, these data were not available for all patients.
iven the brittle nature of the patients, operators em-
loyed very short balloon inflations to minimize isch-
mia, thus precluding adequate time to perform Fick or
hermodilution measurements of cardiac output. For the
chocardiographic analysis, 4 patients did not have a
0-day follow-up echocardiogram performed, so we can-
ot completely exclude any late adverse effects of the
mpella device on the aortic valve, although this seems
nlikely given that there was no evidence of injury on the
mmediate post-PCI studies.
onclusions
his study demonstrated that the Impella 2.5 system is safe,
asy to use, and provides effective hemodynamic support
uring high-risk PCI. Based on these data, a pivotal
andomized clinical trial is planned to compare the efficacy
f prophylactic circulatory support during high-risk PCI
ith the Impella 2.5 device versus conventional intra-aortic
alloon pump counterpulsation. peprint requests and correspondence: Dr. William W. O’Neill,
eonard M. Miller School of Medicine, University of Miami, P.O.
ox 016099 (R.699), Miami, Florida 33101. E-mail:
oneill@med.miami.edu.
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APPENDIX
or a list of PROTECT I Trial clinical sites and principal investigators,
lease see the online version of this article.
